详细说明
Purity
>90%, by SDS-PAGE with silver staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to induce VEGF secretion by PC‑3 human prostate cancer cells. The ED 50 for this effect is 1-5 μg/mL
Source
E. coli-derived Asn2-His491, with an N-terminal Met and 6-His tag
Accession #
N-terminal Sequence
AnalysisMet
Predicted Molecular Mass
56 kDa
SDS-PAGE
55 kDa, reducing conditions
8424-VF |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in HEPES, NaCl, EDTA, TCEP and Tween. | ||
Reconstitution Reconstitute at 500 μg/mL in sterile PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Images
| Recombinant Human PBEF/Visfatin (Catalog # 8424-VF) induces VEGF secretion by PC‑3 human prostate cancer cells. The ED50 for this effect is 1-5 μg/mL |
Background: PBEF/Visfatin
PBEF, also called Visfatin and NAMPT, is a dimeric type II phosphoribosyltransferase (1). It was initially identified as a secreted cytokine that synergized with IL-7 and SCF to stimulate early stage B cells (2). Human PBEF is predominantly expressed in bone marrow, liver, and muscle, with lower levels found in placenta, kidney, heart, and lung (2). Human PBEF shares 96% and 95% amino acid sequence identity with mouse and rat PBEF, respectively. PBEF has been identified both as an intracellular and as an extracellular protein. Within the cell, PBEF converts nicotinamide to nicotinamide mononucleotide (NMN), which is the rate limiting step in the production of nicotinamide adenine dinucleotide (NAD+) (3, 4). In the extracellular environment, PBEF has been reported to increase the production of inflammatory cytokines and have an important role in the development of T and B cells (5-7). Additionally, PBEF may promote angiogenesis in vivo in an ERK1/2-dependent manner (8). PBEF has been implicated in several inflammatory diseases, including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis (9). PBEF over‑expression has been observed in many cancer types (10).
References:
Wang, T. et al. (2006) Nat. Struct. Mol. Biol. 13:661.
Samal, B. et al. (1994) Mol. Cell. Biol. 14:1431.
Rongvaux, A. et al. (2002) Eur. J. Immunol. 32:3225.
Revollo, J.R. et al. (2007) Cell Metab. 6:363.
Ognjanovic, S. and G.D. Bryant-Greenwood (2002) Am. J. Obstet. Gynecol. 187:1051.
Tanaka, M. et al. (2007) Biochem. Biophys. Res. Commun. 359:194.
Rongvaux, A. et al. (2008) J. Immunol. 181:4685.
Kim, S.R. et al. (2007) Biochem. Biophys. Res. Commun. 357:150.
Sun, Z. et al. (2013) Cytokine Growth Factor Rev. 24:433.
Shackelford, R.E. et al. (2013) Genes Cancer 4:447.
Long Name:
Pre-B-Cell Colony-Enhancing Factor 1
Entrez Gene IDs:
10135 (Human); 59027 (Mouse); 297508 (Rat)
Alternate Names:
EC 2.4.2.12; MGC117256; NAmPRTase; NAMPT; nicotinamide phosphoribosyltransferase; NMPRTase; PBEF; PBEF1; PBEF1110035O14Rik; PBEF1DKFZp666B131; Pre-B cell-enhancing factor; pre-B-cell colony enhancing factor 1; Pre-B-cell colony-enhancing factor 1; VF; Visfatin